Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E. Budde(City Of Hope National Medical Center), Nancy L. Bartlett(Washington University in St. Louis), Miguel Canales(Hospital Universitario La Paz), Keith Fay(The University of Melbourne), Shen Yin, Matthew J. Matasar(Rutgers, The State University of New Jersey), Sascha Dietrich(European Molecular Biology Organization), Michael C. Wei(The Royal Melbourne Hospital), Chan Y. Cheah(The University of Western Australia), Sarit Assouline(Jewish General Hospital), Antonia Kwan, Matthew Ku(St Vincent's Hospital Melbourne), Stephen J. Schuster(Hospital of the University of Pennsylvania), John Kuruvilla(Princess Margaret Cancer Centre), Chi‐Chung Li, Elicia Penuel, Huang Huang(Roche (Canada)), Laurie H. Sehn(BC Cancer Agency), Pratyush Giri(Royal Adelaide Hospital), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center)
Cited by 429
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c
|Genes & Development|2000|1.3k